What does the Chromosome 4q25 Single Nucleotide Polymorphisms test measure?

Why is Chromosome 4q25 Single Nucleotide Polymorphisms measured?

Genome-wide association studies have identified 4q25 variants as the strongest common genetic predictors of atrial fibrillation, conferring approximately 1.5–2× risk per copy of the high-risk allele in European-ancestry populations. The genotype does not cause AF in isolation but interacts with age, hypertension, structural heart disease, and other environmental factors to determine an individual's cumulative risk. Knowledge of elevated genetic susceptibility may inform risk stratification, enhance patient engagement in lifestyle modification, and guide decisions about anticoagulation thresholds and monitoring intensity, though it does not substitute for clinical risk scores.

Reference ranges

Standard reference

Reported as genotype (e.g., CC, CT, TT) with associated relative risk; population reference is ancestrally dependent.

Functional medicine optimal

N/A — results are genotypes, not quantitative levels; risk is expressed as fold-change or percentile relative to population.

Units

genotype

Reference ranges vary by laboratory and assay platform. Interpret in context of the issuing laboratory's stated range.